What a 31% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 25 of 27 of this archive, newest first.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The route did not close because of a rule about peptides.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
The route did not close because of a rule about peptides.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
The route did not close because of a rule about peptides.
Reported from the analysis, not from a warning notice.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Reported from the analysis, not from a warning notice.